诺泰生物: 诺泰生物：关于自愿披露通过药品GMP符合性检查的公告

Core Viewpoint - Jiangsu Notai Aosaino Biopharmaceutical Co., Ltd. has successfully passed the GMP compliance inspection for its tablet production line, which is expected to strengthen its production management and quality system for formulation products, providing a solid foundation for market expansion [1]. Group 1: GMP Compliance Inspection - The company received the GMP compliance inspection notice from Jiangsu Provincial Drug Administration, confirming that its Lianyungang factory's tablet production line meets the requirements of the Drug Production Quality Management Standards [1]. - The inspection was conducted at the company's facility located at 82-17 (B floor), 82-19, Jinqiao Road [1]. Group 2: Impact on the Company - The successful GMP compliance inspection is aligned with the company's operational philosophy of "time-leading, technology-leading," which aims to build a technological advantage [1]. - This achievement is expected to positively impact the company's future development and provide a strong guarantee for continuous market expansion in formulations [1].